NCT00034489View on ClinicalTrials.gov

A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients With Metastatic Breast Cancer.

PHASE2CompletedINTERVENTIONAL

Timeline

Start Date

Not specified

Conditions

Breast Neoplasms

Interventions

DRUG

pemetrexed

DRUG

gemcitabine

Trial Locations (1)

Unknown

Rochester

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT00034489 - A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients With Metastatic Breast Cancer. | Biotech Hunter | Biotech Hunter